It is often easy to speak about the achievements of our clients, but we sometimes underestimate our own successes – pushing them into the shadows, thinking that the milestones our teams reach don’t matter as much. However, after numerous conversations with industry peers and demo calls with potential clients, we realized something important: the numbers our own Pharmacovigilance (PV) team delivers every month are truly impressive—and not many companies in the market can compete with them.

That’s why we’ve decided to step out of the shadows, show off a little, and share the story behind our PV team’s success.

At DrugCard, our PV team may be small in size- just three dedicated professionals-but their impact spans across the globe. With precision, expertise, and the support of our AI-powered platform, they deliver high-quality pharmacovigilance services that our clients can rely on.

Global Reach with Local Expertise

Our PV team manages 11 local literature monitoring projects and 3 global monitoring projects. These projects cover 22 countries across multiple regions. We support both human health and veterinary pharmaceuticals worldwide. In veterinary medicine, patient safety directly improves animal welfare.

What makes this achievement even more impressive is the diversity of the sources. Each country has literature published in different languages, requiring careful screening and expert evaluation to ensure that no safety information is missed.

Why Marketing Authorization Holders Choose Us

Pharmaceutical companies and Marketing Authorization Holders (MAHs) often face challenges in maintaining consistent, compliant pharmacovigilance operations across multiple markets. Local regulatory requirements, linguistic diversity, and the sheer volume of literature can overwhelm internal teams.

That’s why many MAHs prefer to outsource pharmacovigilance services to trusted partners like DrugCard. By partnering with us, they gain:

• Access to specialized expertise without the cost of hiring additional in-house staff.
• Compliance assurance across multiple markets and therapeutic areas.
• Efficiency and scalability through our unified AI-powered DrugCard platform, designed specifically for PV specialists.

Our platform helps clients cut routine manual tasks by 60%, ensuring that safety experts can focus on analysis and decision-making rather than administrative burdens.

July Achievements in Numbers

In July, our PV team of three successfully delivered impressive results:

• 16,153 articles from local non-indexed journals were monitored, leading to the identification of 85 cases & safety information.
• 33,231 articles from global indexed sources (PubMed) were screened, with 22 cases & safety information identified.

This demonstrates not only the efficiency of our processes but also the scale of impact a small, highly skilled team can achieve when supported by cutting-edge technology.

The Human Factor Behind the Numbers

Behind every statistic is the dedication of our PV team, whose meticulous work ensures that critical safety information is captured and reported. Their contribution strengthens regulatory compliance, builds trust with our partners, and ultimately protects patients and animals worldwide.

Looking Ahead

We are expanding globally while staying committed to reliable, efficient, and innovative pharmacovigilance services. Our solutions help MAHs meet regulations and focus on developing safe, effective medicines.
At DrugCard, we are proud of our Pharmacovigilance team’s global achievements. We remain dedicated to supporting clients with excellence and innovation. If you consider outsourcing PV activities, our team is ready to assist. Submit your request through the contact form, and we will prepare a tailored proposal.